Ashland Inc. ASH
Regular-session close
After hours · Nov 20, 6:02 PM ET
- YTD
- +23.40%
- 1 year
- +50.27%
5D -2.60 (-3.39%)
- Market cap
- 3.32B
- Revenue (ttm)
- 1.86B
- Profit margin
- 0.21%
- EPS (ttm)
- 0.53
- Shares out
- 45.79M
- P/E ratio
- 136.60
- Forward P/E
- 14.75
- Dividend
- 1.68 (2.27%)
- Ex-dividend date
- Sep 1, 2026
- YTD return
- +23.40%
- 1-year return
- +50.27%
- Volume
- 513.03K
- Avg volume
- 652.39K
- Open
- 73.74
- Previous close
- 74.12
- Day's range
- 72.30 – 74.58
- 52-week range
- 48.19 – 79.50
- Beta
- 0.36
- Analysts
- Buy
- Price target
- 82.45 (+13.9%)
- Earnings date
- Feb 1, 2027
- 50-day average
- 72.12
Key statistics
- 200-day average
- 64.66
- Enterprise value
- 4.40B
- PEG ratio
- 1.23
- Price / sales
- 1.78
- Price / book
- 1.80
- Payout ratio
- 106.73%
- Revenue growth
- 4.40%
- Free cash flow
- 325.62M
- Total cash
- 480.00M
- Total debt
- 1.47B
- Return on equity
- 1.33%
- Short % of float
- 12.49%
Fundamental scorecard
12 of 25 checks passed on ASH’s reported financials
12of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 2 of 5
- Financial health 2 of 5
- Dividend 4 of 5
Statements to Jun 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 73.00
- Target (mean)
- 82.45
- Target (high)
- 90.00
- Strong buy1
- Buy8
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 1, 2027
Expected Feb 1, 2027. Consensus EPS estimate 0.38281.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 1, 2027 | Dec 30, 2026 | 0.3834 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | 1.27 | 1.12 | -0.15 | -11.81% |
| Jul 28, 2026 | Jun 30, 2026 | 0.985 | 1.02 | +0.04 | +3.55% |
| Apr 28, 2026 | Mar 31, 2026 | 0.97 | 0.91 | -0.06 | -6.19% |
| Feb 2, 2026 | Dec 31, 2025 | 0.23 | 0.26 | +0.03 | +13.04% |
| Nov 4, 2025 | Sep 30, 2025 | 1.17 | 1.08 | -0.09 | -7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Nov 5, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 5, 2026 | UBS | main | Buy | Buy |
| Aug 6, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Jul 31, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Jul 30, 2026 | UBS | main | Buy | Buy |
About Ashland Inc.
Ashland Inc. provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; and nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; agricultural chemicals; diagnostic films; and fine chemicals. Its Personal Care segment provides a range of natural, nature-derived, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. Its Intermediates segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. and changed its name to Ashland Inc. in August 2022. Ashland Inc. was founded in 1924 and is headquartered in Wilmington, Delaware.
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Country
- United States
- Website
- ashland.com
News
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026
Adaptive Biotechnologies Highlights clonoSEQ's Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
Reviewing Perimeter Solutions (NYSE:PRM) & Ashland (NYSE:ASH)
Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional
Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models Wells Fargo Maintains Equal-Weight on Ashland, Raises Price Target to $80
JP Morgan Maintains Overweight on Ashland, Raises Price Target to $82
Ashland Q4 2026 Earnings Call Transcript
Your note
Sign in to keep a note on ASH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASSIS ALESSANDRA FACCIN | Officer | Conversion of Exercise of derivative security | Nov 12, 2026 | 9,046 |
| BONI ERIC N. | Officer | Sale | Dec 4, 2024 | 22,319 |
| DRURY EILEEN | Officer | Conversion of Exercise of derivative security | Nov 15, 2026 | 8,758 |
| HARRISON SUZAN F | Director | Conversion of Exercise of derivative security | Jan 22, 2025 | 1,931 |
| KULKARNI ASHISH K | Director | Conversion of Exercise of derivative security | Jan 20, 2026 | 2,113 |
| LAMPKIN ROBIN E | General Counsel | Conversion of Exercise of derivative security | Nov 15, 2026 | 8,753 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.63% | 5,784,382 | 418.79M | Sep 29, 2026 |
| Standard Investments LLC | 9.88% | 4,525,001 | 327.61M | Sep 29, 2026 |
| Cooperman, Leon G. | 7.53% | 3,450,000 | 249.78M | Sep 29, 2026 |
| Dimensional Fund Advisors LP | 5.74% | 2,628,122 | 190.28M | Sep 29, 2026 |
| Franklin Templeton, Inc. | 5.56% | 2,547,004 | 184.40M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.01% | 2,294,550 | 166.13M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Value Investors Trust-FRANKLIN SMALL CAP VALUE FUND | 4.02% | 1,841,188 | 133.30M | Jul 30, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,629,402 | 117.97M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 1,454,480 | 105.30M | Jun 29, 2026 |
| MFS SERIES TRUST XI-MFS Mid Cap Value Fund | 2.80% | 1,283,827 | 92.95M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.62% | 1,201,351 | 86.98M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.30% | 1,051,330 | 76.12M | Jun 29, 2026 |
